Tau Pathology and Parietal White Matter Lesions Have Independent but Synergistic Effects on Early Development of Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Background: White matter lesions (WMLs) are a common finding in patients with dementia. This study investigates the relationship between WMLs, hyperphosphorylated tau (P-tau) in cerebrospinal fluid (CSF) and apolipoprotein E (APOE) ε4 genotype in prodromal Alzheimer's disease (AD). Methods: Baseline levels of tau, P-tau and β-amyloid 1-42 in CSF, the presence of WMLs in the brain, and the APOE genotype were ascertained in 159 patients with mild cognitive impairment (MCI) and 38 cognitively healthy controls. Results: After 5.7 years, 58 patients had developed AD. In this group, patients with normal levels of CSF P-tau had higher levels of WMLs in the parietal regions than those with pathological P-tau levels (p < 0.05). Also, patients without APOE ε4 alleles had more WMLs in the parietal lobes than those with at least one allele (p < 0.05). MCI patients with pathological P-tau levels and parietal WMLs showed a greater risk of developing AD than those with just one of the two pathological parameters. Conclusions: We suggest that WMLs in parietal lobes and tau pathology likely have independent but synergistic effects on the reduction of the cognitive reserve capacity of the brain. In patients with a more low-grade AD pathology, WMLs in the parietal lobes might increase the risk of developing dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stern, Y. (2009) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2009.03.004 · Cited by 2,943
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992 · cited 1×
“Neuropathological studies have shown that a relatively large subgroup of AD patients also have vascular pathology [37, 38] .”
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 1×
“The procedure followed The Alzheimer’s Association flow chart for LP and CSF sample processing [19] .”
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 1×
“Earlier work has firmly established the value of CSF biomarkers in predicting conversion from MCI to AD [33–36] .”
Self-citationBrain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590 · cited 2×
“While previous studies have investigated the role of WMLs in full-blown dementia due to AD [12, 13] , less is known about how these changes affect patients with milder memory complaints.”
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Buchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664
Visser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70139-5 · Cited by 614
Self-citationBuerger, K., Ewers, M., Pirttila, T., Zinkowski, R., Alafuzoff, I., Teipel, S. J., DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., et al. (2006) · Brain · doi:10.1093/brain/awl269 · Cited by 586
Bennett, D. A., Schneider, J. A., Wilson, R. S., Bienias, J. L., & Arnold, S. E. (2004) · Archives of Neurology · doi:10.1001/archneur.61.3.378 · Cited by 526 · cited 1×
“In contrast, the amount of tau-containing neurofibrillary tangles seems to be associated with the stage of cognitive decline throughout the course of the disease [28–31] .”
Brain reserve hypothesis in dementia
Fratiglioni, L., & Wang, H.-X. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-12103 · Cited by 499 · cited 1×
“Clin-icopathological studies have shown that many elderly people with quite extensive pathological AD-related lesions in the brain do not clinically manifest cognitive impairment, suggesting that structural and functional compensations could buffer the effects of neuropathology [48] .”
Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease
Esiri, M. M., Nagy, Z., Smith, M. Z., Barnetson, L., & Smith, A. D. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02355-7 · Cited by 493
A life course approach to cognitive reserve: a model for cognitive aging and development?
Richards, M., & Deary, I. J. (2005) · Annals of Neurology · doi:10.1002/ana.20637 · Cited by 331 · cited 1×
“The reserve can be viewed as the sum of the lifetime input of factors, some offering protection and some increasing vulnerability [49] .”
Measuring cognitive reserve based on the decomposition of episodic memory variance
Reed, B. R., Mungas, D., Farias, S. T., Harvey, D., Beckett, L., Widaman, K., Hinton, L., & DeCarli, C. (2010) · Brain · doi:10.1093/brain/awq154 · Cited by 271 · cited 1×
“Some people progress to dementia, while others barely show any change at all [4] .”
Staekenborg, S. S., Koedam, E. L. G. E., Henneman, W. J. P., Stokman, P., Barkhof, F., Scheltens, P., & van der Flier, W. M. (2009) · Stroke · doi:10.1161/strokeaha.108.531343 · Cited by 139 · cited 1×
“A few studies have shown that WMLs in people with MCI increase the risk of future dementia [8, 9] , but others contradict this finding [10, 11] .”
Cited by
Hu, H.-Y., Ou, Y.-N., Shen, X.-N., Qu, Y., Ma, Y.-H., Wang, Z.-T., Dong, Q., Tan, L., & Yu, J.-T. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.11.007 · Cited by 279
The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment
Tosto, G., Zimmerman, M. E., Hamilton, J. L., Carmichael, O. T., Brickman, A. M., & Initiative, A. D. N. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.014 · Cited by 112
“Based on our previous observations with parietal lobe WMH and a recent report that showed that parietal WMH and tau have synergistic effects on predicting progression from MCI to AD [20], we hypothesized that parietal lobe WMH in particular would modify the effect of tau pathology on brain atrophy and clinical decline…”
BackgroundResultWeaver, N. A., Doeven, T., Barkhof, F., Biesbroek, J. M., Groeneveld, O. N., Kuijf, H. J., Prins, N. D., Scheltens, P., Teunissen, C. E., van der Flier, W. M., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.08.001 · Cited by 71
“By contrast, studies on the relationship between WMH burden and CSF p-tau are scarce and provide conflicting results (Hertze et al., 2013; Marnane et al., 2016).”
BackgroundResultSahara, N., Perez, P. D., Lin, W.-L., Dickson, D. W., Ren, Y., Zeng, H., Lewis, J., & Febo, M. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.12.009 · Cited by 70
“In addition, there is mounting experimental support for a role of tau in white matter (WM) degeneration during the early etiology of AD (Amlien et al., 2013; Bartzokis et al., 2004; Hertze et al., 2013) and tauopathy mouse models (Lin et al.”
Cerebrospinal fluid β-amyloid42 and neurofilament light relate to white matter hyperintensities
Osborn, K. E., Liu, D., Samuels, L. R., Moore, E. E., Cambronero, F. E., Acosta, L. M. Y., Bell, S. P., Babicz, M. A., Gordon, E. A., Pechman, K. R., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.03.028 · Cited by 51
Metadata
- Authors
- Hertze, J., Palmqvist, S., Minthon, L., & Hansson, O.
- Venue
- Dementia and Geriatric Cognitive Disorders Extra
- Publisher
- S. Karger AG
- Published
- 2013-04-19
- Volume
- 3
- Issue
- 1
- Pages
- 113-122
- ISSN
- 1664-5464 (ISSN-L)
- OpenAlex
- W2157526119
- Cited by
- 25
- References
- 16
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.